JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Functional Characterisation of the ATOH1 Molecular Subtype Indicates a Pro-Metastatic Role in Small Cell Lung Cancer

  • 0Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
Biorxiv : the Preprint Server for Biology +

|

February 26, 2024

|

February 26, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A novel subtype of Small Cell Lung Cancer (SCLC) is driven by the transcription factor ATOH1. This oncogenic driver promotes tumor survival and metastasis, suggesting new therapeutic targets.

Area Of Science

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background

  • Small Cell Lung Cancer (SCLC) exhibits molecular heterogeneity based on transcription factor (TF) expression.
  • Previous research identified SCLC subtypes linked to ASCL1, NEUROD1, POU2F3, and immune genes.
  • An additional subtype characterized by the neurogenic TF ATOH1 was noted in a Circulating tumour cell-Derived eXplant (CDX) model biobank.

Purpose Of The Study

  • To investigate the role of the neurogenic transcription factor ATOH1 in Small Cell Lung Cancer (SCLC).
  • To determine if ATOH1 functions as an oncogenic driver in SCLC.
  • To explore ATOH1's impact on tumor cell survival and metastasis.

Main Methods

  • Detection of ATOH1 protein in preclinical SCLC models (CDX) and clinical samples.
  • Analysis of ATOH1's regulatory role in neurogenesis and differentiation in CDX models.
  • Assessment of ATOH1's requirement for cell survival in ex vivo CDX cultures.
  • Evaluation of ATOH1 depletion effects on tumor growth and liver metastasis in vivo.

Main Results

  • ATOH1 protein was detected in a subset of SCLC preclinical models and clinical samples.
  • In CDX models, ATOH1 regulated neurogenesis and differentiation.
  • ATOH1 was essential for the survival of ATOH1-positive CDX cells ex vivo.
  • In vivo, ATOH1 depletion reduced tumor growth and liver metastasis.

Conclusions

  • ATOH1 is validated as a bona fide oncogenic driver in Small Cell Lung Cancer.
  • ATOH1 plays critical roles in tumor cell survival and promotes metastasis.
  • Further research into ATOH1-driven vulnerabilities and predictive biomarkers for targeted therapies is warranted.